SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Capitainer Begins Clinical Sampling for HbA1c FDA 510(k) Study

Capitainer has initiated clinical sampling for an HbA1c FDA 510(k) study.

Related stories